[EFFECT] NeuroSense Therapeutics Ltd. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

11/26/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	November 25, 2025 4:00 P.M.

Form:

F-3

CIK:	0001875091
Company Name:	NeuroSense Therapeutics Ltd.
File Number:	333-291122

Source: View Original Filing on SEC EDGAR

Neurosense Therapeutics Ltd

NASDAQ:NRSN

NRSN Rankings

#5713 Ranked by Market Cap

N/A Ranked by Dividends

NRSN Latest News

Nov 24, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 3, 2025

NeuroSense to Host Investor Webinar on December 8, 2025

Oct 6, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Sep 10, 2025

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 4, 2025

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NRSN Latest SEC Filings

Nov 24, 2025

[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

Nov 21, 2025

[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

Oct 28, 2025

[F-3] NeuroSense Therapeutics Ltd. Foreign Issuer Shelf Registration

Oct 6, 2025

[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

Sep 25, 2025

[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

NRSN Stock Data

Market Cap 34.75M

Float 23.30M

Insiders Ownership 29.68%

Institutions Ownership 1.8%

Short Percent 1.09%

Industry Biotechnology

Sector Healthcare

Website Link

Country Israel

City Herzliya